Loading clinical trials...

Parkinson's Foundation PD GENEration Genetic Registry | Clinical Trials | Clareo Health

RECRUITING

Parkinson's Foundation PD GENEration Genetic Registry

NCT04994015•Parkinson's Foundation

View on ClinicalTrials.gov

Summary

Development of a central repository for PD-related genomic data for future research.

Detailed Description

The purpose of this study is to develop a central repository for PD-related genomic data by individuals who consent to deposit their data and bank their residual DNA obtained through clinical genetic testing for future research use.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Study Population 1: PWP (open for recruitment)
•1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.
•2. Willingness to undergo genetic testing, and choose to be informed of genetic testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).
•3. Capacity to give full informed consent in writing or electronically, and have read and signed the informed consent forms (ICFs) based on site clinician's determination.
•4. Able to perform study activities (including completion of either online, in-person or paper surveys).
•Study Population 2: People at risk of developing PD (not open for recruitment)
•1\. Family members of Study Population 1 may be invited to participate in the study if confirmatory genetic testing is deemed necessary by the genetic testing laboratory.

Exclusion Criteria

•1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.
•2. Individuals who have received a blood transfusion within the past 3 months.
•3. Individuals who have active hematologic malignancies such as lymphoma or leukemia.
•4. Individuals who have had a bone marrow transplant within the past 5 years.
•5. Under the age of 18

Locations (56)

University of Alabama Birmingham

Birmingham, Alabama, United States

MD First Research

Chandler, Arizona, United States

Barrow Neurological Institute

Phoenix, Arizona, United States

University of Arkansas

Fayetteville, Arkansas, United States

University of California San Diego (UCSD)

La Jolla, California, United States

University of California Los Angeles

Los Angeles, California, United States

University of California San Francisco (UCSF)

San Francisco, California, United States

University of Colorado Anschutz

Aurora, Colorado, United States

Hartford Healthcare

Hartford, Connecticut, United States

Aventura Neurology - Visionary Investigators Network

Aventura, Florida, United States

Key Dates

Start Date

December 20, 2020

Primary Completion Date

June 30, 2026

Completion Date

July 1, 2026

Last Updated

May 21, 2025

Enrollment

25,000

ESTIMATED participants

Conditions

Parkinson's Disease

Interventions

Lab Assay for seven genetic variants for Parkinson's Disease

DEVICE

Contacts

Kamalini Ghosh, MS

CONTACT

1-800-473-4636 kghosh@parkinson.org

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGPHASE1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Parkinson's Foundation PD GENEration Genetic Registry

Inclusion Criteria

Exclusion Criteria

Deep Brain Stimulation Therapy in Movement Disorders

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations